ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Oragenics (OGEN) Seeks Answer to Antibiotic Resistance

Updated on April 3, 2014

Oragenics: Small Company with Big Ideas

Oragenics is a small healthcare company focused on novel antibiotics and oral health products. The company is engaged in the search for new antibiotic compounds to combat the growing problem of antibiotic resistant infections.

The need for novel antibiotics is growing as more and more bacteria become resistant to known antibiotics. Antibiotic resistance has been called one of the world's most pressing public health problems. According to the Centers for Disease Control, there are at least 2 million antibiotic-resistant infections and 23,000 people die each year as a result.

Novel Antibiotics

Lantibiotics are a class of antibiotics showing great promise in fighting antibiotic resistant infections. Since the first lantibiotic was discovered in 1927, more than 60 different lantibiotics have been reported. Nisin is the only lantibiotic to be used commercially so far. It has been used in food preservatives for over 40 years in more than 80 countries without widespread occurrence of bacterial resistance.

Oragenics has 6 issued and 2 pending patents relating to lantibiotics. Scientists at Oragenics discovered the lantibiotic MU1140. MU1140 is active at low concentrations against most Gram-positive bacteria against which it has been tested. Infections caused by Gram-positive bacteria are responsible for a large proportion of serious infections worldwide.

DPOLT stands for Differentially Protected Orthogonal Lantionine. In layman’s terms, DPOLT is Oragenic’s patented method of using organic chemistry to make lantibiotics. According to the company, laboratory testing of lantibiotics has been hindered by the difficulty in obtaining sufficient amounts of the molecules, or in sufficient purity. DPOLT technology represents a cost-effective method of manufacturing lantibiotics in sufficient quantities to move testing forward. In the patent application for DPOLT, the company states, “This method can provide a steady stream of novel antibiotics for, e.g., therapeutic applications.”

Oragenics CEO

The Intrexon Connection

Intexon makes the list as one of the hottest IPO’s of 2013. The company was founded by billionaire Randal J. Kirk who is one of the most successful biotech company developers in the United States. Kirk believes Intrexon is blazing a new path to more efficient drug development. He told Forbes magazine in August of this year, “I’ve been a biotech investor for 27 years, and Intrexon is by far the best thing I’ve ever seen.”

Intrexon’s business model is based on entering ECC’s, or Exclusive Channel Collaboration agreements with other companies in the biotech industry. The company’s revenue comes from nine of these ECC agreements. Intrexon has an ECC agreement with Oragenics to develop and commercialize lantibiotics – notably MU1140. Intrexon is betting on Oragenics and the collaboration has met with initial success. On October 31of this year, Oragenics announced that it had successfully engineered a genetically modified host to generate analogs of MU1140. Analogs are compounds that have similar structure and similar chemical properties.

The Road Ahead

I have focused on Oragenics’ role in developing molecules in the laboratory and ultimately products for the marketplace to combat antibiotic-resistant infections. There is an urgent need for new antibiotics and Oragenics is working to fill that need. However, real revenue from lantibiotics is still years away. In the meantime, Oragenics is generating revenue from its oral health products. Probiora3 is a proprietary blend of beneficial bacteria that fights tooth decay. Oragenics is competing with the likes of 3M and Colgate-Palmolive in this arena.

Sales from the company’s oral health care products declined from $1.4 million in 2011 to $1.3 million last year. Oragenics is working hard to increase distribution of Probiora3 products, but sales revenue increases are dependent on the success of marketing efforts. These efforts include clinical trials that could allow the company to expand the claims it can make about its oral care products.

Oragenics recently completed a public stock offering of 4.4 million shares at a price of $2.50 per share. Despite this recent sale, the company has not been significantly increasing the number of shares outstanding within recent years which is a good sign. Based on latest financial disclosure Oragenics Inc has 34.9 M of shares currently outstanding. This is 86% lower than that of the Healthcare sector and 87% lower than that of the Biotechnology industry.

Insider holdings are a good indicator of the confidence of company insiders in the prospects of the company. Insiders hold some 43% of Oragenics’ shares. Current cash is expected to last until mid-2014 supporting the Intrexon lantibiotics collaboration and growth of the oral probiotics products. The collaboration with Intrexon is a sign of significant potential for Oragenics. Randal Kirk’s record in biotech investments speaks for itself. What can we realistically expect from this company? They hope to achieve the first-ever synthetic route to commercial-scale production of a lantibiotic. That is a very tall order and an exciting prospect. Clinical trials are expected to begin in 2014. The enormous potential and tremendous need for lantibiotics make Oragenics a company worth watching and a story worth following.

Oragenics Update

On January 13, 2014 Oragenics (OGEN) stock price shot up 32.4% to $4.25 per share. Oragenics was the second leading gainer on its exchange that day. This unusual increase happened on a down day for Wall Street. The company issued a press release explaining their policy of not commenting on unusual market activity. I have since found no explanation or rumor that would explain the jump that day. As of this writing (Mar. 7, 2014) the price has settled back to $3.36 per share.

This is what the company recently had to say about the prospects for commercialization of its lantibiotic MU1140:

MU1149 will likely compete directly with antibiotic drugs such as vancomycin and newer drugs, including Cubicin (daptomycin) and Zyvox (linezolid). Given the growing resistance of target pathogens to even new antibiotics, we believe that there is ample room in the marketplace for additional antibiotics. Many of our competitors are taking approaches to drug development differing from our approach, including using traditional screening of natural products;
genomics to identify new targets, and combinatorial chemistry to generate new chemical structures. Competition in the pharmaceutical industry is based on drug safety, efficacy, ease of use, patient compliance, price, marketing, and distribution. Our lantibiotic development will depend on our success in developing MU1140 and/or analogs and to the point of commercialization or partnership and in the process securing and protecting our intellectual property.


    0 of 8192 characters used
    Post Comment

    • profile image


      4 years ago

      Some genuinely prize content on this internet site, bookmarked. deafcdkdeadg

    • profile image


      4 years ago

      Sorry to hear about your family member. We never seem to knw where answers will come from but they do come!

    • Bishop55 profile image


      4 years ago from USA

      I lost a family member to MRSA staph. As we evolve it appears viruses do as well, and so our need for stronger drugs continues...


    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

    Show Details
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)